Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?

antibody-drugs conjugates (ADCs) and oral selective ER degraders (SERDs) (11,12). In a recent paper by Rugo et al. published in the Journal of Clinical Oncology the use of one such ADC, sacituzumab-govitecan (SG) in ER+/HER2− disease is explored (11)

[1]  P. Neven,et al.  Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting , 2023, Cancer Research.

[2]  S. Im,et al.  Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy , 2023, Cancer Research.

[3]  Benjamin Haibe-Kains,et al.  The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER+ breast cancer with mitotic aberrations , 2022, Science advances.

[4]  D. Segara,et al.  Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status , 2022, Drug design, development and therapy.

[5]  A. Bardia,et al.  Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[7]  P. Neven,et al.  Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Min Hwan Kim,et al.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.

[9]  E. Winer,et al.  Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. , 2022, The New England journal of medicine.

[10]  F. André,et al.  Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) , 2022, Cancer Research.

[11]  L. Chow,et al.  Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  S. Loi,et al.  ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Somerfield,et al.  Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Bardia,et al.  Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). , 2021, Journal of Clinical Oncology.

[15]  P. Fasching,et al.  Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Piccart,et al.  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.

[17]  H. Rugo,et al.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer , 2021, Targeted Oncology.

[18]  Anna Lee,et al.  Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[19]  P. Neven,et al.  Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer , 2020, Breast Cancer Research and Treatment.

[20]  C. Desmedt,et al.  Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. , 2020, Journal of the National Cancer Institute.

[21]  F. de Braud,et al.  Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications , 2020, Breast Cancer Research.

[22]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[23]  M. Piccart,et al.  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review , 2019, Current Treatment Options in Oncology.

[24]  H. Iwata,et al.  MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.

[25]  W. Tilley,et al.  Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. , 2018, Journal of medicinal chemistry.

[26]  A. Jager,et al.  Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial , 2018, BMC Cancer.

[27]  D. Root,et al.  Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. , 2018, Cancer discovery.

[28]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.